Foot and Mouth Disease News and Research RSS Feed - Foot and Mouth Disease News and Research

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Integrins help cells communicate with and adapt to their environment. Also cancer cells depend on their properties to survive and spread throughout the body. Now scientists at the Technical University of Munich have successfully developed a small, highly active molecule that binds to a specific integrin which operates in many types of cancer. [More]
Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or "sIPV") candidate. [More]
CRISPR tool unlocks potential for novel treatments across different therapeutic areas

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

CRISPR is one of the most exciting advances in gene-based medicine in decades. A uniquely powerful tool for editing the genome, it allows scientists to manipulate DNA with unprecedented precision by deleting unwanted or faulty genes and replacing them with different ones. Its promise in this field of medicine is immense, unlocking the potential for novel treatments across a wide range of therapeutic areas. [More]
Loyola pediatrician reveals signs and symptoms of childhood rashes

Loyola pediatrician reveals signs and symptoms of childhood rashes

Sniffles, stomach bugs, fever and sore throats are often associated with viruses, but rashes are common in children with viral infections as well. [More]
Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013. [More]
Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC. [More]
GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. [More]
SIB Swiss Institute of Bioinformatics designated as FAO Reference Centre for bioinformatics

SIB Swiss Institute of Bioinformatics designated as FAO Reference Centre for bioinformatics

The Food and Agriculture Organization of the United Nations (FAO) has appointed SIB Swiss Institute of Bioinformatics as the FAO Reference Centre for bioinformatics. [More]
GenVec reports net loss of $1.7 million for second quarter 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. [More]
Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. [More]
Study reveals new invasion mechanism of Enterovirus 71

Study reveals new invasion mechanism of Enterovirus 71

A new study determines glycosylation and pH-dependent conformational changes of virus receptor SCARB2 as crucial for EV71 attachment, entry and uncoating. [More]
Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. [More]
GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. [More]
Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms. [More]
First broad-spectrum drugs to combat human rhinoviruses

First broad-spectrum drugs to combat human rhinoviruses

Scientists are reporting progress in the search for the first broad-spectrum drugs to combat human rhinoviruses (HRVs), which cause humanity's most common infectious diseases. [More]
New approach to beef trade could positively transform livelihoods for farmers, reduce threat to wildlife movements

New approach to beef trade could positively transform livelihoods for farmers, reduce threat to wildlife movements

A new study by the Wildlife Conservation Society's Animal & Human Health for the Environment And Development (AHEAD) Program, World Wildlife Fund (WWF), and regional partners finds that a new approach to beef production in southern Africa could positively transform livelihoods for farmers and pastoralists, while helping to secure a future for wildlife and wildlife-based tourism opportunities. [More]
Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility. [More]
Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Sinovac Biotech Ltd., a leading provider of vaccines in China, announced today that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C. [More]
Australian, Singapore researchers join hands to combat disease-causing bugs

Australian, Singapore researchers join hands to combat disease-causing bugs

The fight against a number of significant infectious diseases in the Asia-Pacific region has been given a boost through a new research collaboration between the National Health and Medical Research Council in Australia and the Agency for Science, Technology and Research in Singapore. [More]
Findings provide structural basis for development of drugs to fight enterovirus 71 infection

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children. [More]
Advertisement
Advertisement